Feedback
Settings

Settings

Goto Application

280,665 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28,067
1.WO/2025/241355PYRIMIDINE-BASED IONIC LIQUID AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 27.11.2025
Int.Class C07D 239/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
20having two double bonds between ring members or between ring members and non-ring members
 Appl.No PCT/CN2024/117228 Applicant EML MEDICAL TECHNOLOGIES INC. Inventor LI, Xuezheng
The present disclosure relates to the field of ionic liquids, and specifically to a pyrimidine-based ionic liquid, a preparation method and use thereof. The pyrimidine-based ionic liquid is named as [A] X, and a structural formula of the pyrimidine-based ionic liquid is shown as follows: (I) wherein [A] is derived from an aminoalcohol compound, R 1 represents a C1-C4 alkyl group, and R 2 represents a hydrogen or hydroxyl group. The pyrimidine-based ionic liquid has the advantages of low viscosity, stability to air and water, good compatibility with ssolutes, excellent dissolving capacity and so on, and can be widely applied to industry, particularly to the biomedical field.
2.WO/2025/242702ENZYMATIC PROCESS FOR PRODUCING N-ACETYL GALACTOSAMINE CLUSTERS
WO - 27.11.2025
Int.Class C12P 19/44
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
44Preparation of O-glycosides, e.g. glucosides
 Appl.No PCT/EP2025/063914 Applicant GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED Inventor FUERST, Douglas E.
The invention relates to a novel process for generating N-acetylgalactosamine (GalNAc) clusters using a nitrilase and conjugating said GalNAc clusters to oligonucleotides, such as oligonucleotides for use in therapy. In particular, the nitrilase is used to catalyse the conversion of a trinitrile intermediate to a triacid intermediate.
3.WO/2025/242235DOUBLE-STRANDED RNA CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 27.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CN2025/100475 Applicant SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD Inventor LU, Yinsuo
The present invention relates to a double-stranded RNA conjugate, a preparation method therefor, and the use thereof. The double-stranded RNA conjugate comprises: a first nucleic acid molecule, a second nucleic acid molecule, and a linker; the first nucleic acid molecule is connected to the second nucleic acid molecule by means of the linker; the linker is connected to the first nucleic acid molecule and the second nucleic acid molecule by means of a phosphate ester (p) or a thiophosphate ester (s), and the linker is selected from a structure represented by formula (I).
4.WO/2025/244124METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER
WO - 27.11.2025
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No PCT/JP2025/018722 Applicant SUMITOMO CHEMICAL COMPANY, LIMITED Inventor TAKESHITA, Reo
The present invention provides a method for efficiently producing a nucleic acid oligomer, particularly a method for efficiently oxidizing a nucleic acid precursor that has a phosphite triester bond. Specifically, the present invention provides a method which is for producing, via the phosphoramidite method, a nucleic acid compound that has, at the 5' terminal, a nucleotide represented by formula (I) and in which a nucleic acid that has at least one phosphorothioate bond is produced, said method comprising a step for reacting: a precursor that has, at the 5' terminal, a phosphite triester bond represented by formula (II); an aromatic hydrocarbon or an aromatic heterocyclic compound that has a conjugate acid pKa of less than 5; and an oxidizing solution that contains iodine, pyridine, and water. [The substituents in formulas (I) and (II) are as defined in the description.]
5.3042567SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF THE NRARP GENE
ES - 21.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 16766270 Applicant Sylentis SAU Inventor JIMENEZ, Ana Isabel
6.WO/2025/240962APTAMER BASED BINDING-INDUCED CONFORMATIONAL SWITCHING SENSORS AND USES THEREOF
WO - 20.11.2025
Int.Class C12Q 1/6816
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6816characterised by the detection means
 Appl.No PCT/US2025/030015 Applicant EMORY UNIVERSITY Inventor SALAITA, Khalid S.
This disclosure relates to devices and methods for signaling surface concentrations of biomolecules on particles or other surfaces. In certain embodiments, this disclosure contemplates methods for detecting surface concentrations of biomolecules on a cell or other particle separated by a distance comprising contacting a particle comprising multiple antigens on the surface of the particle with a nucleobase polymer complex comprising a first aptamer domain, a second aptamer domine, and a double stranded reporter domain.
7.20250353870GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF
US - 20.11.2025
Int.Class C07H 5/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
5Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
04to nitrogen
06Aminosugars
 Appl.No 19289408 Applicant RISEN (SUZHOU) PHARMA TECH CO., LTD. Inventor Jiasheng LU

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.

embedded image

8.WO/2025/237408MODIFIED NUCLEOSIDE, DOUBLE-STRANDED RNA MOLECULE COMPRISING SAME, AND USE
WO - 20.11.2025
Int.Class C07H 19/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
 Appl.No PCT/CN2025/095456 Applicant CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD. Inventor ZANG, Chao
The present invention relates to a modified nucleoside, and a double-stranded RNA molecule comprising the modified nucleoside in a seed region of an antisense strand. At least one modified nucleoside is introduced into the seed region of the antisense strand of the double-stranded RNA molecule, such that a target gene is silenced, and the off-target effect of the double-stranded RNA molecule is suppressed. The present invention further relates to a use of the modified nucleoside in preparation of a double-stranded RNA molecule, and a pharmaceutical composition containing the double-stranded RNA molecule, used for preventing and treating a disease.
9.20250352972HIGHLY ACCURATE DE NOVO POLYNUCLEOTIDE SYNTHESIS
US - 20.11.2025
Int.Class B01J 19/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
19Chemical, physical or physico-chemical processes in general; Their relevant apparatus
 Appl.No 19233645 Applicant Twist Bioscience Corporation Inventor Bill James PECK

Methods, systems, compositions, and devices for the manufacturing of high-quality building blocks, such as polynucleotides, are described herein. Processes described herein provide for efficient washing of residual reagents, solvents, or byproducts from previous synthetic steps to allow for the generation of polynucleotides with low error rates. Processes described herein also provide for reduction in deletion rates during chemical nucleic acid synthesis. Further, methods and devices described herein allow for the rapid construction and assembly of large libraries of highly accurate polynucleotides.

10.WO/2025/240886PATTERNED DOUBLE STRANDED OLIGONUCLEOTIDES
WO - 20.11.2025
Int.Class A61K 31/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
 Appl.No PCT/US2025/029809 Applicant IONIS PHARMACEUTICALS, INC. Inventor SWAYZE, Eric E.
Provided are oligomeric agents, methods, and pharmaceutical compositions for reducing the amount or activity of a target RNA in a cell or animal, and in certain instances reducing the amount of a target protein in a cell or animal.
# -